GPR54 / KISS1R
also: GPR54, KISS1R, kisspeptin receptor, KiSS-1 receptor
Kisspeptin receptor on hypothalamic GnRH neurons. Loss-of-function variants cause failure or delay of puberty in people, which is how its role in reproduction was identified.
GPR54, now officially designated KISS1R (KISS1 receptor), is a G-protein-coupled receptor generally described as coupling to Gq/11 and found on GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus. Its ligands are the kisspeptins (Kp-54, Kp-14, Kp-13 and Kp-10), which are cleavage products of the KISS1 gene. Kisspeptin signalling through this receptor is described as a key permissive signal for the pulsatile GnRH release that drives the reproductive axis.
Why it matters in peptide research
The receptor's role in reproduction was identified in people with loss-of-function variants who had idiopathic hypogonadotropic hypogonadism, a failure or delay of puberty with intact pituitary and gonadal tissue. This established kisspeptin-receptor signalling as upstream of the other reproductive hormones.
Kisspeptin has been given to people in small physiology and dose-finding studies, mostly in healthy volunteers. These studies, and what they did and did not find, are set out in the Kisspeptin-10 evidence summary. The same summary separates kisspeptin-10 from the longer kisspeptin-54, which was used in the human studies of IVF and of low sexual desire.
Nutritional status, sex steroids, photoperiod and stress are reported to act on kisspeptin neurons, which is why the receptor is discussed where metabolic and reproductive health meet, for example in hypothalamic amenorrhoea linked to energy deficit.
Peptides that act on this receptor
- Kisspeptin-10. The minimal bioactive fragment of kisspeptin. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists kisspeptin-10 in category 2 under the 503A interim policy (added 29 September 2023) and says: "Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization." The kisspeptin-10 page gives FDA's full entry.
- Kisspeptin-54. The full-length form, with a longer duration of action than kisspeptin-10 in male mice according to the evidence summary above.
Common misconceptions
Kisspeptin is not testosterone or an LH analogue. In the usual description it acts upstream, on GnRH neurons, so any effect on LH and testosterone is indirect.
Prolonged exposure does not always give a prolonged effect. In human studies of continuous kisspeptin-10 infusion, the gonadotropin response faded: in 4 healthy men given a continuous subcutaneous infusion for 5 days, gonadotropins were back at vehicle level while testosterone stayed raised. In the same study the authors report that daily 8-hour infusions for 12 days sustained gonadotropin increases (mean LH rise +1.68 on day 1 and +1.14 on day 12, against -0.16 on vehicle).
Related on this site
- Kisspeptin-10 evidence summary
- PT-141 + Kisspeptin — combination evidence review
- GnRH (glossary)
- KNDy neurones (glossary)
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: unsourced claims that kisspeptin analogues avoid pituitary desensitisation, that kisspeptin-10 is used in fertility protocols and that pulsatile schedules matter were removed; human infusion findings and FDA's kisspeptin-10 statement were added.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Related glossary entries
GHRH receptor
Growth Hormone Releasing Hormone receptor expressed on pituitary somatotropes that triggers GH secretion when activated by endogenous GHRH or synthetic analogues.
Pituitary somatotropes
GH-secreting acidophilic cells of the anterior pituitary that constitute 40–50% of its cell population and serve as the exclusive source of pulsatile growth hormone output.